Pub Date : 2024-09-02Epub Date: 2024-07-25DOI: 10.1080/15321819.2024.2381524
Shaimaa Elsayed Ramadan Genena, Maha A F Hamouda, Norhan M Salama, Enas S Zahran, Asmaa A Abdel Latif, Ashraf A Dawood
Background and objectives: The type I interferon (IFN) signature has been found to be overactivated in many systemic autoimmune diseases. This may be explained by impaired regulation of interferon-stimulated genes (ISGs) as well as interferon-induced protein 44 (IFI44) expression via their regulatory mechanisms via interferon regulatory factors (IRFs).
Patients and methods: This case-control study includes two groups: 50 RA patients and 50 healthy controls. The quantification of IFI44 and IRF4 expression levels by the real-time PCR technique was estimated. Disease Activity Score-28 (DAS-28) was estimated for RA patients only.
Results: Among the RA patients, there were statistically significant increased ESR, CRP, TLC, RF, and anti-CCP levels (p value < 0.001) and significant increased expression of the IFI44 and IRF4 genes (p value < 0.001). There was a significant positive correlation between the IFI44 and IRF4, and there was a significant correlation between both and ESR and anti-CCP among RA patients. At a cutoff point of 1.95, IFI44 shows higher sensitivity and specificity values than IRF4 for the diagnosis of RA.
Conclusion: IFI44 was more sensitive for RA diagnosis than IRF4. IFI44 and IRF4 overexpression could be promising predictors of RA diagnosis and might become useful clinical tools to guide therapeutic strategies.
背景和目的:在许多系统性自身免疫疾病中,I型干扰素(IFN)特征被发现过度激活。这可能是由于干扰素刺激基因(ISGs)以及干扰素诱导蛋白44(IFI44)通过干扰素调节因子(IRFs)的调节机制表达受损所致:这项病例对照研究包括两组:50 名 RA 患者和 50 名健康对照组。采用实时 PCR 技术对 IFI44 和 IRF4 的表达水平进行了量化估计。仅对 RA 患者的疾病活动度评分-28(DAS-28)进行了估计:结果:在 RA 患者中,ESR、CRP、TLC、RF 和抗CCP 水平均有统计学意义的显著增加(p 值 p 值 结论:IFI44 对 RA 患者更敏感:IFI44 对 RA 诊断的敏感性高于 IRF4。IFI44和IRF4的过度表达有可能成为RA诊断的预测指标,并有可能成为指导治疗策略的有用临床工具。
{"title":"Interferon-induced protein 44 (<i>IFI44</i>) and interferon regulatory factor 4 (<i>IRF4</i>) gene expression in rheumatoid arthritis.","authors":"Shaimaa Elsayed Ramadan Genena, Maha A F Hamouda, Norhan M Salama, Enas S Zahran, Asmaa A Abdel Latif, Ashraf A Dawood","doi":"10.1080/15321819.2024.2381524","DOIUrl":"10.1080/15321819.2024.2381524","url":null,"abstract":"<p><strong>Background and objectives: </strong>The type I interferon (IFN) signature has been found to be overactivated in many systemic autoimmune diseases. This may be explained by impaired regulation of interferon-stimulated genes (ISGs) as well as interferon-induced protein 44 (IFI44) expression via their regulatory mechanisms via interferon regulatory factors (IRFs).</p><p><strong>Patients and methods: </strong>This case-control study includes two groups: 50 RA patients and 50 healthy controls. The quantification of IFI44 and IRF4 expression levels by the real-time PCR technique was estimated. Disease Activity Score-28 (DAS-28) was estimated for RA patients only.</p><p><strong>Results: </strong>Among the RA patients, there were statistically significant increased ESR, CRP, TLC, RF, and anti-CCP levels (<i>p</i> value < 0.001) and significant increased expression of the IFI44 and IRF4 genes (<i>p</i> value < 0.001). There was a significant positive correlation between the IFI44 and IRF4, and there was a significant correlation between both and ESR and anti-CCP among RA patients. At a cutoff point of 1.95, IFI44 shows higher sensitivity and specificity values than IRF4 for the diagnosis of RA.</p><p><strong>Conclusion: </strong>IFI44 was more sensitive for RA diagnosis than IRF4. IFI44 and IRF4 overexpression could be promising predictors of RA diagnosis and might become useful clinical tools to guide therapeutic strategies.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"432-451"},"PeriodicalIF":0.0,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-02Epub Date: 2024-07-23DOI: 10.1080/15321819.2024.2383676
Heba A S Bazid, Alaa H Marae, Bassant Farag, Rania Abdallah Abdallah
Background: Alopecia areata (AA), an immune-mediated disorder, is marked by temporary, nonscarring hair loss. The bulge area is protected from immune attacks by immune privilege; however, recent studies demonstrated immune cells infiltrating the bulge area.
Objective: This study aims to investigate the immunohistochemical expression of the sex-determining region Y-box 9 (SOX9) and cluster of differentiation 34 (CD34) in AA patients as markers of hair follicle stem cells (HFSCs) and progenitor cells, respectively.
Methods: Immunohistochemical staining of SOX9 and CD34 was applied on skin samples of 20 AA patients and 20 healthy controls.
Results: SOX9 and CD34 were significantly lower in lesional samples of cases compared to perilesional and control skin biopsies. Furthermore, SOX9 level was negatively correlated with the severity of alopecia tool score (SALT score) among the studied AA patients. Moreover, lowered SOX9 expression was present in patients with recurrent attacks.
Conclusions: The significant reduction of stem cell markers (SOX9 and CD34) in our studied AA cases signifies the pathological affection of HFSCs and their progeny in AA. This is thought to cause a loss of competence in generating new hair in some AA cases, which needs to be validated in further research.
Limitations of the study: This study has a small sample size.
背景:斑秃(AA)是一种免疫介导的疾病,以暂时性、非瘢痕性脱发为特征。隆起区受到免疫特权的保护,免受免疫攻击;但最近的研究表明,免疫细胞浸润了隆起区:本研究旨在调查 AA 患者中性决定区 Y-box 9(SOX9)和分化簇 34(CD34)分别作为毛囊干细胞(HFSCs)和祖细胞标志物的免疫组化表达情况:方法:对20名AA患者和20名健康对照者的皮肤样本进行SOX9和CD34免疫组化染色:结果:与皮损周围和对照组皮肤活检样本相比,病例皮损样本中的 SOX9 和 CD34 水平明显较低。此外,在所研究的 AA 患者中,SOX9 水平与脱发严重程度工具评分(SALT 评分)呈负相关。此外,复发患者的SOX9表达也有所降低:结论:在我们研究的AA病例中,干细胞标志物(SOX9和CD34)明显减少,这表明AA患者的高频间充质干细胞及其后代发生了病理变化。研究的局限性:本研究的样本量较小。
{"title":"The value of immunohistochemical expression of SOX9 and CD34 in alopecia areata.","authors":"Heba A S Bazid, Alaa H Marae, Bassant Farag, Rania Abdallah Abdallah","doi":"10.1080/15321819.2024.2383676","DOIUrl":"10.1080/15321819.2024.2383676","url":null,"abstract":"<p><strong>Background: </strong>Alopecia areata (AA), an immune-mediated disorder, is marked by temporary, nonscarring hair loss. The bulge area is protected from immune attacks by immune privilege; however, recent studies demonstrated immune cells infiltrating the bulge area.</p><p><strong>Objective: </strong>This study aims to investigate the immunohistochemical expression of the sex-determining region Y-box 9 (SOX9) and cluster of differentiation 34 (CD34) in AA patients as markers of hair follicle stem cells (HFSCs) and progenitor cells, respectively.</p><p><strong>Methods: </strong>Immunohistochemical staining of SOX9 and CD34 was applied on skin samples of 20 AA patients and 20 healthy controls.</p><p><strong>Results: </strong>SOX9 and CD34 were significantly lower in lesional samples of cases compared to perilesional and control skin biopsies. Furthermore, SOX9 level was negatively correlated with the severity of alopecia tool score (SALT score) among the studied AA patients. Moreover, lowered SOX9 expression was present in patients with recurrent attacks.</p><p><strong>Conclusions: </strong>The significant reduction of stem cell markers (SOX9 and CD34) in our studied AA cases signifies the pathological affection of HFSCs and their progeny in AA. This is thought to cause a loss of competence in generating new hair in some AA cases, which needs to be validated in further research.</p><p><strong>Limitations of the study: </strong>This study has a small sample size.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"452-466"},"PeriodicalIF":0.0,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-02Epub Date: 2024-08-13DOI: 10.1080/15321819.2024.2388614
Nadia ElMenshawy, Manal Ibrahim Fouda, Mohamed Mofreh, Heba Hisham El-Etriby, Manal O Elnenaei, Mohamed Eissa
Multiple myeloma (MM) is a prevalent yet incurable hematologic malignancy. Despite the proven efficacy of proteasome inhibitors in treating MM, resistance to Bortezomib-based treatments persists in a subset of patients. This case control study explores the potential of circulating endothelial progenitor cells (EPCs) as biomarkers for predicting response to Proteasome Inhibitor based therapy combined with Dexamethasone in MM patients. This study was conducted on 105 MM patients receiving bortezomib plus dexamethasone therapy and 90 healthy individuals as a control group. Utilizing 8-color multi-parameter flow cytometry, we assessed the levels of circulating EPCs, identified through CD34 FITC and CD309 PE markers at diagnosis and after one treatment cycle (4 weeks). Our findings revealed that patients exhibiting poor response to therapy showed significantly higher CD34/CD309 values than those with a good response (p < 0.001). The delineation of response based on CD34/CD309 expression was established with a cutoff ≤ 0.9 for percentage (yielding 100% sensitivity and 94.1% specificity) and ≤ 12.5 for absolute value (also with 100% sensitivity and 94.1% specificity). These results underscore the potential of EPC population levels, as quantified by CD34/CD309, to serve as a predictive biomarker for immunomodulatory treatment in MM patients undergoing Proteasome Inhibitor and Dexamethasone therapy.
{"title":"Impact of CD34/CD309 expression in circulating endothelial progenitor cells on prognosis and response to bortezomib therapy in multiple myeloma.","authors":"Nadia ElMenshawy, Manal Ibrahim Fouda, Mohamed Mofreh, Heba Hisham El-Etriby, Manal O Elnenaei, Mohamed Eissa","doi":"10.1080/15321819.2024.2388614","DOIUrl":"10.1080/15321819.2024.2388614","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a prevalent yet incurable hematologic malignancy. Despite the proven efficacy of proteasome inhibitors in treating MM, resistance to Bortezomib-based treatments persists in a subset of patients. This case control study explores the potential of circulating endothelial progenitor cells (EPCs) as biomarkers for predicting response to Proteasome Inhibitor based therapy combined with Dexamethasone in MM patients. This study was conducted on 105 MM patients receiving bortezomib plus dexamethasone therapy and 90 healthy individuals as a control group. Utilizing 8-color multi-parameter flow cytometry, we assessed the levels of circulating EPCs, identified through CD34 FITC and CD309 PE markers at diagnosis and after one treatment cycle (4 weeks). Our findings revealed that patients exhibiting poor response to therapy showed significantly higher CD34/CD309 values than those with a good response (<i>p</i> < 0.001). The delineation of response based on CD34/CD309 expression was established with a cutoff ≤ 0.9 for percentage (yielding 100% sensitivity and 94.1% specificity) and ≤ 12.5 for absolute value (also with 100% sensitivity and 94.1% specificity). These results underscore the potential of EPC population levels, as quantified by CD34/CD309, to serve as a predictive biomarker for immunomodulatory treatment in MM patients undergoing Proteasome Inhibitor and Dexamethasone therapy.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"481-491"},"PeriodicalIF":0.0,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-02Epub Date: 2024-07-04DOI: 10.1080/15321819.2024.2376034
Rabiyah Al Adawiah, Apon Zaenal Mustopa, Sri Budiarti, Rifqiyah Nur Umami, Ai Hertati, Herman Irawan, Muh Chaeril Ikramullah, Arwansyah Arwansyah, Jendri Mamangkey, Isti Kartikasari, Huda Salahudin Darusman
The available prophylactic vaccines for human papillomavirus (HPV) in the market are only effective against specific types of HPV, rendering them ineffective for other types of HPV infections. The objective of this research is to investigate the stability of the recombinant protein constructed, namely chimeric L1/L2 protein from HPV type 52, with improved cross-neutralization ability. The 3D model, predicted using Alphafold, Robetta, I-Tasser, and refined with Galaxy Refinement, is validated using Ramachandran plot analysis. The stability is verified through molecular dynamics simulations, considering parameters such as RMSD, RMSF, Rg, and SASA, where stable conditions are observed. The chimeric L1/L2 protein from HPV type 52 is purified using affinity chromatography, and the His-tag is cleaved using SUMO protease to obtain pure chimeric protein with the size of ~ 55 kDa. Western blot analysis confirms binding to anti-L1 HPV type 52 polyclonal antibody. The obtained vaccine candidate can be utilized as an effective prophylactic vaccine against HPV.
{"title":"Molecular dynamics simulation and purification of chimeric L1/L2 protein from <i>human papillomavirus</i> type 52 expressed in <i>Escherichia coli</i> BL21 (DE3).","authors":"Rabiyah Al Adawiah, Apon Zaenal Mustopa, Sri Budiarti, Rifqiyah Nur Umami, Ai Hertati, Herman Irawan, Muh Chaeril Ikramullah, Arwansyah Arwansyah, Jendri Mamangkey, Isti Kartikasari, Huda Salahudin Darusman","doi":"10.1080/15321819.2024.2376034","DOIUrl":"10.1080/15321819.2024.2376034","url":null,"abstract":"<p><p>The available prophylactic vaccines for human papillomavirus (HPV) in the market are only effective against specific types of HPV, rendering them ineffective for other types of HPV infections. The objective of this research is to investigate the stability of the recombinant protein constructed, namely chimeric L1/L2 protein from HPV type 52, with improved cross-neutralization ability. The 3D model, predicted using Alphafold, Robetta, I-Tasser, and refined with Galaxy Refinement, is validated using Ramachandran plot analysis. The stability is verified through molecular dynamics simulations, considering parameters such as RMSD, RMSF, Rg, and SASA, where stable conditions are observed. The chimeric L1/L2 protein from HPV type 52 is purified using affinity chromatography, and the His-tag is cleaved using SUMO protease to obtain pure chimeric protein with the size of ~ 55 kDa. Western blot analysis confirms binding to anti-L1 HPV type 52 polyclonal antibody. The obtained vaccine candidate can be utilized as an effective prophylactic vaccine against HPV.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"395-414"},"PeriodicalIF":0.0,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-03Epub Date: 2024-06-11DOI: 10.1080/15321819.2024.2365699
Farshad Foroughi, Roghaye Keshavarz Sadegh, Maryam Khalaji, Mahin Lashgari, Amir Javadi, Mehdi Sahmani, Shamim Nonejad, Sanaz Keshavarz Shahbaz
Background: Rheumatoid arthritis (RA) is an autoimmune disease indicated by joint inflammation and cartilage destruction. Matrix metalloproteinase (MMP) enzymes play an influential role in inflammation by affecting the invasion and degradation of anatomical barriers. In this way, the current study investigated the relationship between the MMP-9-1562C/T gene polymorphism and this enzyme's serum level in RA.
Methods: The serum levels of MMP-9 in RA patients and healthy controls were measured using the enzyme-linked immunosorbent assay (ELISA). RA was confirmed using rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and C-reactive protein (CRP). Then the MMP-9-1562C/T gene polymorphism was analyzed utilizing polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Also, multivariate analysis investigated the connection between this polymorphism and the risk of RA.
Results: In this study, the increase of MMP-9 in patients due to the development of single nucleotide polymorphism in the promoter region of this gene (-1562 C→T) was confirmed by increasing the frequency of heterozygous genotype (CT). Logistic regression analysis also demonstrated that the chance of development of RA is higher in people with CT/CC genotype than in other alleles.
Conclusions: We demonstrated that MMP-9-1562C/T gene polymorphism can play a significant role in the occurrence of RA.
背景:类风湿性关节炎(RA)是一种以关节炎症和软骨破坏为特征的自身免疫性疾病。基质金属蛋白酶(MMP)通过影响解剖屏障的侵袭和降解,在炎症中发挥着重要作用。因此,本研究探讨了MMP-9-1562C/T基因多态性与RA血清中该酶水平的关系:方法:采用酶联免疫吸附试验(ELISA)测定 RA 患者和健康对照组血清中 MMP-9 的水平。通过类风湿因子(RF)、抗环瓜氨酸肽(anti-CCP)和 C 反应蛋白(CRP)确认 RA。然后利用聚合酶链反应(PCR)和限制性片段长度多态性(RFLP)分析了 MMP-9-1562C/T 基因的多态性。结果显示,MMP-9-1562C/T基因多态性的增加与RA的发病风险有关:结果:在这项研究中,通过增加杂合基因型(CT)的频率,证实了该基因启动子区单核苷酸多态性(-1562 C→T)的发生导致患者体内 MMP-9 的增加。逻辑回归分析也表明,CT/CC基因型的人患RA的几率高于其他等位基因:结论:我们的研究表明,MMP-9-1562C/T 基因多态性在 RA 的发生中起着重要作用。
{"title":"Association between matrix metalloproteinase-9-1562C/T gene polymorphism and MMP-9 serum level in rheumatoid arthritis.","authors":"Farshad Foroughi, Roghaye Keshavarz Sadegh, Maryam Khalaji, Mahin Lashgari, Amir Javadi, Mehdi Sahmani, Shamim Nonejad, Sanaz Keshavarz Shahbaz","doi":"10.1080/15321819.2024.2365699","DOIUrl":"10.1080/15321819.2024.2365699","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is an autoimmune disease indicated by joint inflammation and cartilage destruction. Matrix metalloproteinase (MMP) enzymes play an influential role in inflammation by affecting the invasion and degradation of anatomical barriers. In this way, the current study investigated the relationship between the MMP-9-1562C/T gene polymorphism and this enzyme's serum level in RA.</p><p><strong>Methods: </strong>The serum levels of MMP-9 in RA patients and healthy controls were measured using the enzyme-linked immunosorbent assay (ELISA). RA was confirmed using rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP), and C-reactive protein (CRP). Then the MMP-9-1562C/T gene polymorphism was analyzed utilizing polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Also, multivariate analysis investigated the connection between this polymorphism and the risk of RA.</p><p><strong>Results: </strong>In this study, the increase of MMP-9 in patients due to the development of single nucleotide polymorphism in the promoter region of this gene (-1562 C→T) was confirmed by increasing the frequency of heterozygous genotype (CT). Logistic regression analysis also demonstrated that the chance of development of RA is higher in people with CT/CC genotype than in other alleles.</p><p><strong>Conclusions: </strong>We demonstrated that MMP-9-1562C/T gene polymorphism can play a significant role in the occurrence of RA.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"362-381"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141306124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-03Epub Date: 2024-05-30DOI: 10.1080/15321819.2024.2358879
Marwa Mohammed Dawoud, Hayam Abd El Samie Aiad, Norhan Safwat Kasem, Enas Abu-Bakr El Khouly, Dalia Rifaat Al-Sharaky
Background: Now, targeted therapy and immunotherapy are promoted. tumour -Associated Macrophages (TAMs) are an essential component of immune-response in breast cancer(BC) with prognostic controversy. Additionally, their recruiting factors are still obscure. Purpose:This study aimed to evaluate the prognostic significance of CD163 and CD47 in BC of No Special Type (BC-NST) and to explore their suggested role in recruiting TAMs.
Material and methods: This immunohistochemical study was conducted on 91 archival specimens of breast cases. Immunoreactivity scores were correlated with TAMs density, clinicopathological data, and survival.
Results: Revealed the highest CD163 expression was detected in the pure DCIS group (p = 0.016), while the highest CD47 expression and high TAMs density were reported in the invasive group (p = 0.008, and p = 0.002 respectively) followed by the DCIS group. In IC-NSTs the CD163 and CD47 scores were associated with poor prognostic parameters like(high grade, advanced stage, distant metastasis, ER negativity,Ki67 index, post-surgical chemotherapy, poor NPI group, high mitotic count, dense infiltration of TAMs, shorter OS). Also, CD47 was associated with the dens infiltration of TAMs in DCIS (p = 0.001). There was a significant correlation between tumour cell expression of CD163 and CD47 in IC-NSTs and DCIS (p = 0.002 and p = 0.009 respectively).
Conclusions: High CD163 and CD47 expressions in both DCIS andIBC are intimately associated, significantly associated with poor prognosis and are important provoking factors of TAMs.
{"title":"Is overexpression of CD163 and CD47 in tumour cells of breast carcinoma implicated in the recruitment of tumour-associated macrophages (TAMs) in tumour microenvironment? immunohistochemical prognostic study.","authors":"Marwa Mohammed Dawoud, Hayam Abd El Samie Aiad, Norhan Safwat Kasem, Enas Abu-Bakr El Khouly, Dalia Rifaat Al-Sharaky","doi":"10.1080/15321819.2024.2358879","DOIUrl":"10.1080/15321819.2024.2358879","url":null,"abstract":"<p><strong>Background: </strong>Now, targeted therapy and immunotherapy are promoted. tumour -Associated Macrophages (TAMs) are an essential component of immune-response in breast cancer(BC) with prognostic controversy. Additionally, their recruiting factors are still obscure. Purpose:This study aimed to evaluate the prognostic significance of CD163 and CD47 in BC of No Special Type (BC-NST) and to explore their suggested role in recruiting TAMs.</p><p><strong>Material and methods: </strong>This immunohistochemical study was conducted on 91 archival specimens of breast cases. Immunoreactivity scores were correlated with TAMs density, clinicopathological data, and survival.</p><p><strong>Results: </strong>Revealed the highest CD163 expression was detected in the pure DCIS group (<i>p</i> = 0.016), while the highest CD47 expression and high TAMs density were reported in the invasive group (<i>p</i> = 0.008, and <i>p</i> = 0.002 respectively) followed by the DCIS group. In IC-NSTs the CD163 and CD47 scores were associated with poor prognostic parameters like(high grade, advanced stage, distant metastasis, ER negativity,Ki67 index, post-surgical chemotherapy, poor NPI group, high mitotic count, dense infiltration of TAMs, shorter OS). Also, CD47 was associated with the dens infiltration of TAMs in DCIS (<i>p</i> = 0.001). There was a significant correlation between tumour cell expression of CD163 and CD47 in IC-NSTs and DCIS (<i>p</i> = 0.002 and <i>p</i> = 0.009 respectively).</p><p><strong>Conclusions: </strong>High CD163 and CD47 expressions in both DCIS andIBC are intimately associated, significantly associated with poor prognosis and are important provoking factors of TAMs.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"342-361"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-03Epub Date: 2024-05-22DOI: 10.1080/15321819.2024.2356639
Shabarni Gaffar, Siti Hesti Nurbayanti, Yeni Wahyuni Hartati, Mia Tria Novianti, Korry Novitriani, Safri Ishmayana, Muhammad Yusuf, Toto Subroto
Single Chain Variable Fragment (scFv), a small fragment of antibody can be used to substitute the monoclonal antibody for diagnostic purposes. Production of scFv in Escherichia coli host has been a challenge due to the potential miss-folding and formation of inclusion bodies. This study aimed to express anti-CHIKV E2 scFv which previously designed specifically for Asian strains by co-expression of three chaperones that play a role in increasing protein solubility; GroEL, GroES, and Trigger Factor. The scFv and chaperones were expressed in Origami B E. coli host under the control of the T7 promoter, and purified using a Ni-NTA column. Functional assay of anti-CHIKV-E2 scFv was examined by electrochemical immunosensor using gold modified Screen Printed Carbon Electrode (SPCE), and characterized by differential pulses voltammetry (DPV) using K3[Fe(CN)6] redox system and scanning microscope electron (SEM). The experimental condition was optimized using the Box-Behnken design. The results showed that co-expression of chaperone increased the soluble scFv yield from 54.405 μg/mL to 220.097 µg/mL (~5×). Furthermore, scFv can be used to detect CHIKV-E2 in immunosensor electrochemistry with a detection limit of 0.74048 ng/mL and a quantification limit of 2,24388 ng/mL. Thus, the scFv-anti-CHIKV-E2 can be applied as a bioreceptor in another immunoassay method.
{"title":"Expression of scFv-anti-CHIKV-E2 in <i>Escherichia coli</i> with chaperones Co-expression, and its functional assay by electrochemical immunosensor.","authors":"Shabarni Gaffar, Siti Hesti Nurbayanti, Yeni Wahyuni Hartati, Mia Tria Novianti, Korry Novitriani, Safri Ishmayana, Muhammad Yusuf, Toto Subroto","doi":"10.1080/15321819.2024.2356639","DOIUrl":"10.1080/15321819.2024.2356639","url":null,"abstract":"<p><p>Single Chain Variable Fragment (scFv), a small fragment of antibody can be used to substitute the monoclonal antibody for diagnostic purposes. Production of scFv in <i>Escherichia coli</i> host has been a challenge due to the potential miss-folding and formation of inclusion bodies. This study aimed to express anti-CHIKV E2 scFv which previously designed specifically for Asian strains by co-expression of three chaperones that play a role in increasing protein solubility; GroEL, GroES, and Trigger Factor. The scFv and chaperones were expressed in Origami B <i>E. coli</i> host under the control of the T7 promoter, and purified using a Ni-NTA column. Functional assay of anti-CHIKV-E2 scFv was examined by electrochemical immunosensor using gold modified Screen Printed Carbon Electrode (SPCE), and characterized by differential pulses voltammetry (DPV) using K3[Fe(CN)6] redox system and scanning microscope electron (SEM). The experimental condition was optimized using the Box-Behnken design. The results showed that co-expression of chaperone increased the soluble scFv yield from 54.405 μg/mL to 220.097 µg/mL (~5×). Furthermore, scFv can be used to detect CHIKV-E2 in immunosensor electrochemistry with a detection limit of 0.74048 ng/mL and a quantification limit of 2,24388 ng/mL. Thus, the scFv-anti-CHIKV-E2 can be applied as a bioreceptor in another immunoassay method.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"307-324"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141081774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Endometrial hyperplasia (EH), an abnormal proliferation of the endometrial cells, is considered as one of the most common causes of abnormal uterine bleeding. Previous studies have reported that melatonin plays a fundamental role in disease treatment. This study aimed the comparison of the effects of progesterone, as the most common therapeutic approach, and melatonin with progesterone alone in improvement of non-atypical endometrial hyperplasia (NEH) and changes in pro-inflammatory cytokine levels.
Methods: Study population consisted of 40 patients with NEH. Patients were divided into two groups, including 20 subjects treated with melatonin and progesterone and 20 individuals treated with progesterone alone. The blood and endometrial sampling was performed from participants before and after a three-month treatment. The histological examination was microscopically done. The serum levels of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) were measured using ELISA.
Results: There was no significant difference in the diabetes status and mean age between patients treated with progesterone and melatonin and those treated with progesterone alone. The improvement rate in the EH was significantly higher in individuals treated with progesterone and melatonin than those treated with progesterone alone (p < 0.05). Additionally, the patients treated with progesterone and melatonin showed significant increases inIFN-γ and TNF-αlevels compared to the control group (p < 0.001-P < 0.05).
Conclusion: Melatonin supplementation has a beneficial effect in the treatment of EH due perhaps to enhance the level of IFN-γ and TNF-α.
{"title":"Effects of melatonin on disease improvement and serum levels of pro-inflammatory cytokines in patients with non-atypical endometrial hyperplasia.","authors":"Neda Aslany, Zahra Vahedpour, Habibollah Rahimi, Mohsen Masjedi, Hossein Motedayyen","doi":"10.1080/15321819.2024.2371583","DOIUrl":"10.1080/15321819.2024.2371583","url":null,"abstract":"<p><strong>Background: </strong>Endometrial hyperplasia (EH), an abnormal proliferation of the endometrial cells, is considered as one of the most common causes of abnormal uterine bleeding. Previous studies have reported that melatonin plays a fundamental role in disease treatment. This study aimed the comparison of the effects of progesterone, as the most common therapeutic approach, and melatonin with progesterone alone in improvement of non-atypical endometrial hyperplasia (NEH) and changes in pro-inflammatory cytokine levels.</p><p><strong>Methods: </strong>Study population consisted of 40 patients with NEH. Patients were divided into two groups, including 20 subjects treated with melatonin and progesterone and 20 individuals treated with progesterone alone. The blood and endometrial sampling was performed from participants before and after a three-month treatment. The histological examination was microscopically done. The serum levels of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) were measured using ELISA.</p><p><strong>Results: </strong>There was no significant difference in the diabetes status and mean age between patients treated with progesterone and melatonin and those treated with progesterone alone. The improvement rate in the EH was significantly higher in individuals treated with progesterone and melatonin than those treated with progesterone alone (<i>p</i> < 0.05). Additionally, the patients treated with progesterone and melatonin showed significant increases inIFN-γ and TNF-αlevels compared to the control group (<i>p</i> < 0.001-P < 0.05).</p><p><strong>Conclusion: </strong>Melatonin supplementation has a beneficial effect in the treatment of EH due perhaps to enhance the level of IFN-γ and TNF-α.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"382-394"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03Epub Date: 2024-05-11DOI: 10.1080/15321819.2024.2352496
Sara Kamal Rizk, Azza Gaber Antar Farag, Samah El-Ghlban, Israa Salah Eldin Metwally
Objectives: This study aims to examine whether the genetic variants in the genes for Granzyme B (GZMB) and Interferon Induced with Helicase C domain 1 (IFIH1) were associated with psoriasis.
Background: Psoriasis, a papulosquamous skin disease, was initially thought of as a disorder primarily of epidermal keratinocytes but is now recognized as one of the most common immune-mediated disorders. It is caused by the interplay between multiple genetic and environmental risk factors.
Subjects and methods: This case-control study has 65 participants with psoriasis and 65 healthy controls. Real-time PCR was used to genotype GZMB (rs8192917) and IFIH1 (rs35667974).
Results: Genotype occurrence and allelic spreading for both SNPs are in Hardy - Weinberg equilibrium. The genotype and allele distributions of rs35667974 showed no differences between the studied groups. Regarding rs8192917, compared to Group II, there is a statistically significant rise in the CC genotype and C allele in Group I. Higher PASI scores are detected in the C/C and C/T genotypes more than the T/T genotype. Univariate and multivariate analyses revealed that BMI, catalase, MDA, and rs8192917 (C/C) are associated with psoriasis.
Conclusion: GZMB rs8192917 was significantly related to psoriasis risk; its C allele is likewise associated with psoriasis vulnerability. However, our investigation found no link between rs35667974 and psoriasis.
研究目的本研究旨在探讨颗粒酶B(GZMB)和干扰素诱导螺旋酶C域1(IFIH1)基因的遗传变异是否与银屑病有关:背景:银屑病是一种丘疹鳞屑性皮肤病,最初被认为主要是表皮角质细胞的紊乱,但现在被认为是最常见的免疫介导疾病之一。它是由多种遗传和环境风险因素相互作用引起的:这项病例对照研究有 65 名银屑病患者和 65 名健康对照者。采用实时 PCR 对 GZMB(rs8192917)和 IFIH1(rs35667974)进行基因分型:结果:两个 SNP 的基因型发生和等位基因分布均处于 Hardy - Weinberg 平衡状态。rs35667974的基因型和等位基因分布在研究组之间没有差异。关于 rs8192917,与第二组相比,第一组中的 CC 基因型和 C 等位基因在统计学上有显著增加,C/C 和 C/T 基因型的 PASI 评分高于 T/T 基因型。单变量和多变量分析显示,BMI、过氧化氢酶、MDA和rs8192917(C/C)与银屑病相关:结论:GZMB rs8192917与银屑病风险显著相关;其C等位基因同样与银屑病易感性相关。然而,我们的调查发现 rs35667974 与银屑病之间没有关联。
{"title":"Identifying the association between polymorphisms in the GZMB and IFIH1 genes and psoriasis in Egyptians.","authors":"Sara Kamal Rizk, Azza Gaber Antar Farag, Samah El-Ghlban, Israa Salah Eldin Metwally","doi":"10.1080/15321819.2024.2352496","DOIUrl":"10.1080/15321819.2024.2352496","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to examine whether the genetic variants in the genes for Granzyme B (GZMB) and Interferon Induced with Helicase C domain 1 (IFIH1) were associated with psoriasis.</p><p><strong>Background: </strong>Psoriasis, a papulosquamous skin disease, was initially thought of as a disorder primarily of epidermal keratinocytes but is now recognized as one of the most common immune-mediated disorders. It is caused by the interplay between multiple genetic and environmental risk factors.</p><p><strong>Subjects and methods: </strong>This case-control study has 65 participants with psoriasis and 65 healthy controls. Real-time PCR was used to genotype GZMB (rs8192917) and IFIH1 (rs35667974).</p><p><strong>Results: </strong>Genotype occurrence and allelic spreading for both SNPs are in Hardy - Weinberg equilibrium. The genotype and allele distributions of rs35667974 showed no differences between the studied groups. Regarding rs8192917, compared to Group II, there is a statistically significant rise in the CC genotype and C allele in Group I. Higher PASI scores are detected in the C/C and C/T genotypes more than the T/T genotype. Univariate and multivariate analyses revealed that BMI, catalase, MDA, and rs8192917 (C/C) are associated with psoriasis.</p><p><strong>Conclusion: </strong>GZMB rs8192917 was significantly related to psoriasis risk; its C allele is likewise associated with psoriasis vulnerability. However, our investigation found no link between rs35667974 and psoriasis.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"189-209"},"PeriodicalIF":0.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}